Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency

Barth, Florian; Gerber, Peter J; Reichen, Jürg; Dufour, Jean-François; Nicod, Laurent P (2006). Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. European journal of gastroenterology & hepatology, 18(10), pp. 1117-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.meg.0000231749.60889.f7

Full text not available from this repository. (Request a copy)

Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology
04 Faculty of Medicine > Service Sector > Institute of Clinical Pharmacology and Visceral Research (discontinued)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Gerber, Peter; Reichen, Jürg; Dufour, Jean-François and Nicod, Laurent

ISSN:

0954-691X

ISBN:

16957519

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:45

Last Modified:

06 Dec 2013 13:41

Publisher DOI:

10.1097/01.meg.0000231749.60889.f7

PubMed ID:

16957519

Web of Science ID:

000243646000013

URI:

https://boris.unibe.ch/id/eprint/18542 (FactScience: 734)

Actions (login required)

Edit item Edit item
Provide Feedback